Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Risk Assessment

View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Harvard Apparatus Regenerative Technology is: No Data: Cannot be evaluated.

Competitive Comparison of Harvard Apparatus Regenerative Technology's Risk Assessment

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harvard Apparatus Regenerative Technology's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Risk Assessment falls into.

Harvard Apparatus Regenerative Technology (OTCPK:HRGN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Harvard Apparatus Regenerative Technology Risk Assessment Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

84 October Hill Road, Suite 11, Holliston, MA, USA, 01746

Website

https://www.biostage.com

Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.

Executives

Junli He	director	C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling	director	975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc	10 percent owner	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard	director	2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen	director	C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu	officer: President	C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr	officer: Chief Financial Officer	14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green	director, officer: See Remarks	C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor	officer: Chief Scientific Officer	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino	officer: Interim VP of Finance	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez	director	84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge	officer: See Remarks	C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young	director	60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang	director	C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li	director	C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746